` BD1 (BARD1 Life Sciences Ltd) vs S&P/ASX 300 Comparison - Alpha Spread

BD1
vs
S
S&P/ASX 300

Over the past 12 months, BD1 has underperformed S&P/ASX 300, delivering a return of 0% compared to the S&P/ASX 300's +6% growth.

Stocks Performance
BD1 vs S&P/ASX 300

Loading
BD1
S&P/ASX 300
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
BD1 vs S&P/ASX 300

Loading
BD1
S&P/ASX 300
Difference
www.alphaspread.com

Performance By Year
BD1 vs S&P/ASX 300

Loading
BD1
S&P/ASX 300
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
BARD1 Life Sciences Ltd vs Peers

No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

BARD1 Life Sciences Ltd
Glance View

Market Cap
83.3m AUD
Industry
Health Care

BARD1 Life Sciences Ltd. is a biotechnology company, which engages in the provision of medical services. The firm is engaged in research, development, and commercialization of non-invasive diagnostic products for the early detection of cancer. The Company’s technologies include BARD1, SubB2, NET and hTERT. BARD1 is a biomarker platform covering various tumor markers including nucleic acids, proteins, and autoantibodies for early cancer diagnosis.SubB2M is a pan-cancer probe for monitoring cancer treatment response and recurrence across a wide range of cancers. NET is designed to capture and purify biomarkers, including acids, cells, and exosomes. hTERT is an antibody-based assay to detect hTERT, a component of telomerase, in cells.

BD1 Intrinsic Value
Not Available
Back to Top